NewAmsterdam Pharma Company NV Warrant

Yahoo Finance • yesterday

8Dell, 89bio, MBX Biosciences and More Stocks See Action From Activist Investors

13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities. Continue Reading View Comments... Full story

Yahoo Finance • 2 months ago

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025

NewAmsterdam Pharma N.V. -- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzheimer’s disease pathology, in both the full analysis set (p=0.0019) and in ApoE4 carrier... Full story

Yahoo Finance • 2 years ago

NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer

NAARDEN, the Netherlands and MIAMI, Oct. 23, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines fo... Full story

Yahoo Finance • 2 years ago

NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference

NAARDEN, The Netherlands and MIAMI, Sept. 20, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medi... Full story

Yahoo Finance • 2 years ago

NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer

NAARDEN, The Netherlands and MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines fo... Full story

Yahoo Finance • 2 years ago

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

-- Enrollment Completed Several Months Ahead of Schedule, Reflecting Significant Unmet Need and Patient Demand for New Options -- -- Topline Results Expected in 2H 2024 – NAARDEN, the Netherlands and MIAMI, April 24, 2023 (GLOBE NEWSWIR... Full story

Yahoo Finance • 3 years ago

NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors

NAARDEN, the Netherlands and MIAMI, April 03, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on the research and development of transfo... Full story

Yahoo Finance • 3 years ago

NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update

-- Completed business combination with FLAC and closed concurrent, oversubscribed approximately $235 million PIPE, led by Frazier Healthcare Partners and Bain Capital Life Sciences, extending expected cash runway through 2026 -- -- Announ... Full story